FDA
-
-
-
-
-
-
-
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Wells Fargo Starts Nuvalent (NUVL) at Overweight
-
-
-
-
-
-
-
Nuvalent appoints Ron Squarer to board of directors
-
-
-
-
-
-
-
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC
-
-
-
-
-
-
-
Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025
-
-
-
-
-
-
-
Nuvalent starts phase 3 trial of neladalkib for lung cancer patients
-
-
-
-
-
-
-
Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results
-
323,577 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

